Marketing AYUSH and Ayurvedic products in India: the compliance-shaped playbook

Most categories can describe what a product does. Ayurveda largely cannot, at least not in the words a founder would choose. The purchase turns on believing a claim that a photograph cannot prove, and the claim itself is the thing regulation touches hardest. That is why so many Ayurvedic brands end up arguing on price against products making the same vague promise.

This is the brand-building playbook: what the rules actually restrict, how to construct campaigns that survive review, and where trust comes from once the easy claims are off the table. If your immediate problem is ads being rejected by Meta, the narrower guide is why Meta rejects ayurveda and supplement ad claims, and this piece will not repeat that ground. One thing before the detail: this is a marketing article written by a marketing team, not legal advice. Regulatory positions change and depend on how your product is licensed and classified, so confirm anything here with your own compliance or legal counsel before you publish.

First, know which regime you are actually in

Two entirely different rulebooks sit over this shelf, and brands regularly assume the wrong one applies to them. If your product is licensed as an Ayurveda, Siddha, Unani or Homoeopathy drug, its labelling follows the Drugs and Cosmetics Rules and its advertising follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. If it is a food, health supplement or nutraceutical, it sits with FSSAI. In April 2024 the Ministry of AYUSH addressed several problematic advertising practices by AYUSH manufacturers, and one of them was AYUSH drugs or products claiming nutraceutical value, which belongs to the FSSAI domain rather than the AYUSH one. The advisory was reported by NutraIngredients on 1 May 2024. Working out which regime you are in is the first hour of work, not the last, because it decides what your pack, your ads and your landing page are allowed to say.

What the rules actually restrict

The short list that matters to a marketing team:

• You cannot claim nutraceutical value for an AYUSH drug or product. That terminology belongs to FSSAI's framework, not the AYUSH one.
• You cannot say you are approved or certified by the Ministry of AYUSH. The Ministry has stated it does not grant a manufacturing licence or approval for any AYUSH drug or medicine, and that licensing by a State Drug Licensing Authority should not be construed as ministry approval. It has said that carrying such a claim on a label or advertisement would attract legal action against the manufacturer.
• Absolute safety language is treated as misleading. "100 per cent safe", "free from side effects", "guaranteed treatment" and "permanent cure" were named as examples that run against the Consumer Protection Act and related law.
• There is a schedule of diseases a drug may not claim to prevent or cure. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 lists them, and it is long: cancer, diabetes, blindness, cataract, deafness, disorders of the brain and many more. The Ministry's AyushSuraksha portal reproduces the list, alongside the enforcement route: complaints are forwarded to State Licensing Authorities, and gazetted officers appointed under the Act can enter, search and seize.
• If you are on the FSSAI side, claims must be substantiated and must match the label. Claims about reducing the risk of a disease that are not listed in the Schedule need pre-approval from FSSAI before marketing, health-benefit claims are expected to be supported by well-designed human intervention studies, and Section 53 of the FSS Act carries a penalty of up to ₹10 lakh for misleading food advertisements. Cyril Amarchand Mangaldas set the framework out in May 2025; the regulations themselves live on the FSSAI regulations page.

Creators: the rules changed and most briefs have not

Influencer marketing is where compliant brands most often trip, because the brand writes a careful pack and then hands a creator a free hand.

ASCI's Guidelines for Influencer Advertising in Digital Media require a disclosure label wherever a material connection exists between advertiser and influencer, and material connection is defined broadly enough to include free product, even unsolicited, as well as discounts, trips and barter. Disclosures have to be hard to miss rather than buried in hashtags or behind a "see more".

The part specific to this category: for health and nutrition content, ASCI requires the influencer to hold relevant qualifications, such as a medical degree or certification as a nutritionist or dietician, and to disclose those qualifications prominently and upfront. Influencers without them can share generic information that is not in the nature of technical advice. Under the Consumer Protection Act framework enforced by the CCPA, responsibility is shared: the brand is accountable for the product's compliance and for the influencer following the guidelines, and the influencer is accountable for the disclosure and their own endorsement. Translate that into a brief: a scripted claim set creators may use, a list of words they may not, a required qualification disclosure, and a rule that any deviation comes back to you before it goes live.

Build the proof into the funnel, not into the headline

Once the easy claims are gone, the temptation is to say nothing and compete on price. There is a better answer, and Amyra Farms, a premium Ayurvedic foods brand, is the clearest example of it. CAC was too high and ROAS was inconsistent, the premium positioning sailed straight over cold audiences, and the funnel made no distinction between someone discovering the brand and someone ready to buy. Everyone got the same message, so nobody got the right one.

The fix was a true full funnel with distinct creative at each stage:

• Top of funnel earns attention and explains the category, without asking a stranger to accept a mechanism they have not asked about yet.
• Middle of funnel carries the reason to believe: ingredient, sourcing, heritage, the person behind the formulation. For Ayurvedic and supplement brands this stage does most of the work, because the purchase turns on believing something a photograph cannot prove.
• Bottom of funnel removes the last friction for someone already convinced.

The pitch was rewritten rather than just the targeting: scroll-stopping statics for the first impression, founder-led video for credibility, and ingredient-led hooks that made purity, heritage and function impossible to miss. Media went cohort-specific, so new users, repeat buyers and subscription prospects each saw their own offer. Over three months CAC dropped more than 50% and ROAS doubled, with retention deepening at the same time, which means the cheaper customers were not worse customers. Note what was not done: CAC was not cut by discounting, because for a premium Ayurvedic brand that trade destroys the thing being sold.

Put a person behind the claim

Founder-led video does specific work here. A person on camera making a claim is accountable for it in a way a product shot is not, and accountability is the substitute for the medical language you cannot use. It is also cheap enough to produce at the volume a scaling account eats through. The same pattern shows up outside Ayurveda proper: on Pushti Organics, an organic foods brand where trust in sourcing is the actual purchase decision, founder-led video cut CAC by 28% while lifting repeat purchases.

Ritual and culture beat generic wellness

Parasbaagh makes premium hand-plucked functional teas rooted in Ayurveda, and started at zero: no positioning, no story, no paid strategy, product content that looked like it came from five different brands. The correction was one cohesive identity across Instagram, the website and the ads, with a voice rooted in Ayurvedic ritual and culture rather than generic wellness language, which is the crowded end of the category and the hardest place to be remembered.

Then everything was tested, including the products themselves. Sales rose 300%, Meta ROAS reached 3× at daily spends the brand could sustain, and the creative library now holds five-plus proven performers running above 3.5% click-through. That library is the asset: a set of proven hooks is what lets spend increase without cost per result climbing with it.

There is a category lesson underneath. A brand starting from nothing has two problems at once: nobody knows it, and the customer already meets the need with something cheaper already in the kitchen. Advertising solves the first quickly. The second needs a specific reason to switch, and creative testing is how you find the one the market accepts.

Do not let the website be the constraint

Butterfly Ayurveda had no media problem at all. Demand existed. What it met was a site with technical and conversion roadblocks that could not reliably carry a visitor from interest to a completed order, so sales were capped by the shop rather than by the market. Nothing in the reporting flags that: traffic looks fine, interest looks fine, revenue does not follow, and the usual response is to buy more traffic and push more people into the same blocked path. The technical foundation was fixed first, because optimisation testing on an unstable site measures the instability rather than the change, and only then was the conversion path worked end to end.

Legacy and clinical brands: connect the channels, do not just modernise them

British Biologicals is a trusted name in clinical nutrition whose digital presence lagged behind its reputation. Nothing was joined up: website with one team, content with another, paid with an agency, retail with sales, each optimising its own metric honestly while the customer experienced the gaps between them. The clinical trust built offline never followed the customer online, and in this category that costs more than elsewhere, because in a clinic credibility is delivered by a person the buyer already trusts and on a feed that person is absent. The fix was one strategy across website, content and paid media, with every channel given a defined role and D2C connected to the retail and clinical presence rather than competing with it.

A high customer acquisition cost is a symptom, not a diagnosis. Full funnel is the discipline that separates the causes.

A compliance-shaped checklist you can run this week

• Confirm in writing whether each SKU is an AYUSH drug or an FSSAI food or supplement, and file the licence details next to it.
• Write your permitted claim set and your banned word list, and give both to every writer, editor and creator.
• Delete "approved by Ministry of AYUSH", "100 per cent safe", "no side effects", "guaranteed" and "permanent cure" from every asset you own.
• Check ad copy against the pack, line by line. If the ad says something the label does not, one of them is wrong.
• Keep a claims file: the substantiation behind each claim, dated, so a review does not become a scramble.
• Brief creators with a script, a disclosure requirement and the qualification rule for health content.
• Move the reason to believe into mid-funnel creative, where it is being spent on people who have asked the question.
• Take it past your own compliance or legal counsel before it goes live.

If you want help building the funnel and the proof at the same time, that is performance marketing, creative and content and strategy working together, with CRO and web making sure the site is not the constraint. More of this work sits under nutrition and FMCG.